This bill mandates that all individual and group health insurance policies, as well as various health service contracts, provide coverage for prescription insulin drugs and diabetes management devices starting January 1, 2027. Specifically, it requires that the total out-of-pocket cost for a 30-day supply of covered prescription insulin drugs be capped at $35, while coverage for diabetes management devices is limited to $100. Additionally, the bill stipulates that at least one type of insulin from various categories must be covered, and it includes provisions for diabetes self-management education to be provided by trained healthcare professionals.

Furthermore, the bill establishes an appeals process for individuals who cannot take certain prescribed insulin drugs, ensuring they and their healthcare providers can participate meaningfully in the process. It also prohibits any contracts between health service providers and pharmacy benefits managers from including charges that exceed the specified limits. The bill outlines definitions for "device" and "prescription insulin drug," and clarifies that certain existing statutes do not apply to this new section. The implementation of these provisions will be overseen by the commissioner of insurance and the board of healing arts, which will also set training requirements for healthcare providers involved in diabetes education.